Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetic study after oral administration of codeine

Journal of Pharmaceutical and Biomedical Analysis

Volumn 78-79, Issue , 2013, Pages 261-268

  Wu, Xiujun ^a,b   Zhang, Weiping ^c   Bai, Yin ^d   Guo, Tao ^a   Gu, Jingkai ^e  

^a SHENYANG NORTHERN HOSPITAL   (China)

^b University of Traditional Chinese Medicine   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^d Chifeng University   (China)

^e JILIN UNIVERSITY   (China)

Author keywords

Codeine; LC MS MS; Morphine; Morphine 3 glucuronide; Morphine 6 glucuronide

Indexed keywords

CODEINE; DRUG METABOLITE; FORMIC ACID; METHANOL; MORPHINE; MORPHINE 3BETA GLUCURONIDE; MORPHINE 6BETA GLUCURONIDE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADULT; CHROMATOGRAPHY, LIQUID; CODEINE; HUMANS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84875268562     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.02.027     Document Type: Article

References (21)

1. Arora S., Herbert M.E. Myth: codeine is a powerful and effective analgesic. West. J. Med. 2001, 174:428.
2. Yue Q.Y., Svensson J.O., Alm C., Sjöqvist F., Säwe J. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br. J. Clin. Pharmacol. 1989, 28:629-637.
3. Mortimer O., Persson K., Ladona M.G., Spalding D., Zanger U.M., Meyer U.A., Rane A. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin. Pharmacol. Ther. 1990, 47:27-35.
4. Pasternak G.W., Bodnar R.J., Clark J.A., Inturrisi C.E. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 1987, 41:2845-2849.
5. Penson R.T., Joel S.P., Bakhshi K., Clark S.J., Langford R.M., Slevin M.L. Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin. Pharmacol. Ther. 2000, 68:667-676.
6. Penson R.T., Joel S.P., Clark S., Gloyne A., Slevin M.L. Limited phase I study of morphine-3-glucuronide. J. Pharm. Sci. 2001, 90:1810-1816.
7. Teh L.K., Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab. Pharmacokinet. 2012, 27:55-67.
8. Mikus G., Bochner F., Eichelbaum M., Horak P., Somogyi A.A., Spector S. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. J. Pharmacol. Exp. Ther. 1994, 268:546-551.
9. Gasche Y., Daali Y., Fathi M., Chiappe A., Cottini S., Dayer P., Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 2004, 351:2827-2831.
10. Barnes A.J., Kim I., Schepers R., Moolchan E.T., Wilson L., Cooper G., Reid C., Hand C., Huestis M.A. Sensitivity, specificity, and efficiency in detecting opiates in oral fluid with the Cozart Opiate Microplate EIA and GC-MS following controlled codeine administration. J. Anal. Toxicol. 2003, 27:402-407.
11. Geier A., Bergemann D., von Meyer L. Evaluation of a solid-phase extraction procedure for the simultaneous determination of morphine, 6-monoacetylmorphine, codeine and dihydrocodeine in plasma and whole blood by GC/MS. Int. J. Legal. Med. 1996, 109:80-83.
12. Montagna M., Stramesi C., Vignali C., Groppi A., Polettini A. Simultaneous hair testing for opiates, cocaine, and metabolites by GC-MS: a survey of applicants for driving licenses with a history of drug use. Forensic Sci. Int. 2000, 107:157-167.
13. Bogusz M.J., Maier R.D., Erkens M., Driessen S. Determination of morphine and its 3- and 6-glucuronides, codeine, codeine-glucuronide and 6-monoacetylmorphine in body fluids by liquid chromatography atmospheric pressure chemical ionization mass spectrometry. J. Chromatogr. B: Biomed. Sci. Appl. 1997, 703:115-127.
14. Dienes-Nagy A., Rivier L., Giroud C., Augsburger M., Mangin P. Method for quantification of morphine and its 3- and 6-glucuronides, codeine, codeine glucuronide and 6-monoacetylmorphine in human blood by liquid chromatography-electrospray mass spectrometry for routine analysis in forensic toxicology. J. Chromatogr. A. 1999, 854:109-118.
15. Murphy C.M., Huestis M.A. LC-ESI-MS/MS analysis for the quantification of morphine, codeine, morphine-3-beta-d-glucuronide, morphine-6-beta-d-glucuronide, and codeine-6-beta-d-glucuronide in human urine. J. Mass Spectrom. 2005, 40:1412-1416.
16. Claudia C.F., Hoffman K.L., Thomas J.J., Carvalho B., Chu L.F., Drover D.R., Hammer G.B., Christians U., Galinkin J.L. A sensitive assay for the quantification of morphine and its active metabolites in human plasma and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 2011, 400:715-728.
17. Taylor K., Elliott S. A validated hybrid quadrupole linear ion-trap LC-MS method for the analysis of morphine and morphine glucuronides applied to opiate deaths. Forensic Sci. Int. 2009, 187:34-41.
18. US Food and Drug Administration, FDA Guidance for Industry BioanalyticalMethod Validation 2001, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, Rockville, MD.
19. Matuszewski B.K. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. J. Chromatogr. B. 2006, 830:293-300.
20. Liao Q., Deng Y., Xie Z., Pan B., Zhang L. Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. J. Sep. Sci. 2009, 32:202-211.
21. Kirchheiner J., Schmidt H., Tzvetkov M., Keulen J.T., Lötsch J., Roots I., Brockmöller J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007, 7:257-265.